financetom
Business
financetom
/
Business
/
Collegium Pharmaceutical Signs $25 Million Accelerated Share Buyback Deal With Jefferies
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Collegium Pharmaceutical Signs $25 Million Accelerated Share Buyback Deal With Jefferies
May 26, 2025 5:56 AM

10:27 AM EDT, 05/12/2025 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) said Monday that it signed an accelerated share repurchase deal with Jefferies to repurchase $25 million of its common shares.

The deal is part of the company's $150 million share repurchase program that was approved by its board in January 2024, according to the statement.

Collegium Pharmaceutical ( COLL ) said it will pay $25 million to Jefferies in exchange for an initial delivery of 692,281 common shares, which is about 80% of the shares that it expects to buy back under the accelerated share repurchase deal.

The company said the final amount of shares will be based on the volume-weighted average prices of its shares over the term of the accelerated share repurchase agreement, subject to certain adjustments.

Price: 29.86, Change: +0.97, Percent Change: +3.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Bristol-Myers Squibb, SystImmune Report 'Promising' Results for Cancer Drug in Phase 1 Study
Oct 17, 2025
11:10 AM EDT, 10/17/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) and SystImmune said Friday that a phase 1 study of the antibody-drug conjugate iza-bren showed promising anti-tumor activity and manageable safety profile. Presenting data at the European Society for Medical Oncology Congress in Berlin, the companies said the trial showed a 55% confirmed response rate among patients receiving...
VSE to Drive Sustained Growth on Better Sales, Margin Expansion, Deutsche Bank Says
VSE to Drive Sustained Growth on Better Sales, Margin Expansion, Deutsche Bank Says
Oct 17, 2025
10:47 AM EDT, 10/17/2025 (MT Newswires) -- VSE (VSEC) is set to deliver sustained earnings growth driven by above-average sales, margin expansion and disciplined acquisitions, Deutsche Bank said in a note Friday. The firm expects VSE to maintain a low-teens organic earnings before interest, taxes, depreciation, and amortization compound annual growth rate in the years ahead, supporting a low to...
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Canaccord Genuity Group Jumps Near 20%, Comments on Reports of Possible Sale of British Business
Oct 17, 2025
11:09 AM EDT, 10/17/2025 (MT Newswires) -- Canaccord Genuity Group ( CCORF ) , up near 20% to a multi-year high, Friday commented on a news article speculating about a potential sale of Canaccord's UK wealth management business. The company said in a statement that it routinely evaluates strategic initiatives which sometimes involve discussions with potential counterparties, however, there can...
Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts
Novo Nordisk hires US pharma veteran as Trump pricing pressure mounts
Oct 17, 2025
LONDON/COPENHAGEN, Oct 17 (Reuters) - Novo Nordisk has appointed U.S. pharmaceutical executive Greg Miley as its new head of corporate affairs, according to a statement he posted on LinkedIn, as the obesity drugmaker faces growing pressure from the Trump administration on drug pricing. Miley, an American, is currently senior vice president of government affairs at U.S. pharmaceutical giant AbbVie (...
Copyright 2023-2026 - www.financetom.com All Rights Reserved